Volume 125, Issue 3 , Pages 593-599, March 2010
Differential effects of outdoor versus indoor fungal spores on asthma morbidity in inner-city children
Background
Although sensitization to fungal allergens is prevalent in inner-city children with asthma, the relationship between fungal exposure and morbidity is poorly understood.
Objective
We examined relationships between fungal sensitization, exposure, and asthma morbidity in inner-city children.
Methods
Participants were 5 to 11 years old and enrolled in the Inner-City Asthma Study. This report includes the subset of children with at least 1 positive skin test (PST) response to a fungal allergen extract; for these children, indoor and outdoor airborne culturable fungi levels were measured at baseline and throughout the 2-year study. Asthma morbidity measures were collected prospectively. The primary outcome was symptom days per 2 weeks.
Results
At baseline, children with a PST response to a fungal allergen extract had significantly more symptom days compared with those without a PST response to any fungal allergen extract (6.3 vs 5.7 days per 2 weeks, P = .04). During the study, increases in total fungal exposure and indoor Penicillium species exposure were associated with increases in symptom days and asthma-related unscheduled visits. Indoor exposures to total fungi and to Penicillium species were associated with significant increases in unscheduled visits, even after controlling for outdoor fungal levels. Adverse effects associated with exposure to a specific fungus were stronger among children with PST responses to that fungal allergen extract compared with those seen in children with negative skin test responses.
Conclusion
Outdoor fungal exposure is primarily associated with increased asthma symptoms and increased risk of exacerbations in this population.
Key words: Asthma, inner city, airborne fungi, indoor fungi, outdoor fungi, fungal allergens, children
Abbreviations used: DG18, Dichloran glycerol agar, ICAS, Inner-City Asthma Study, MSD, Maximum symptom day, NHLBI, National Heart, Lung, and Blood Institute, NST, Negative skin test, OR, Odds ratio, PST, Positive skin test, UV, Unscheduled visit
Supported by National Institutes of Health grants AI/ES-39769, AI/ES-39900, AI/ES-39902, AI/ES-39789, AI/ES-39901, AI/ES-39761, AI/ES-39785, and AI/ES-39776 from the National Institute of Allergy and Infectious Diseases and the National Institutes of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, and by grant M01 RR00533 from the National Center for Research Resources, National Institutes of Health, Department of Health and Human Services.
Disclosure of potential conflict of interest: J. A. Pongracic receives research support from the National Institute of Allergy and Infectious Diseases and the Food Allergy Project. G. T. O'Connor is a consultant for Sepracor, Inc, and Pulmatrix, Inc. M. L. Muilenberg receives research support from the National Institutes of Health. B. Vaughn is employed by Rho, Inc. D. R. Gold receives grant support from the National Institutes of Health and the US Environmental Protection Agency. W. J. Morgan is a consultant for the Cystic Fibrosis Foundation and Genentech, Inc, and receives grant support from the National Institutes of Health. R. S. Gruchalla is a consultant for GlaxoSmithKline, receives research support from Novartis, and is on the Board of Directors for ABAI. H. E. Mitchell is employed by Rho, Inc, and receives research support from the National Institute of Allergy and Infectious Diseases and the National Institutes of Environmental Health Sciences. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)01584-X
doi:10.1016/j.jaci.2009.10.036
© 2010 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 125, Issue 3 , Pages 593-599, March 2010
